Nellcor buy causes Mallinckrodt loss
One-time charges related to its acquisition of Nellcor Puritan Bennett contributed to a $291.9 million net loss for St. Louis-based Mallinckrodt. The company also reported that earnings in its medical imaging business declined as a result of falling
One-time charges related to its acquisition of Nellcor Puritan Bennett contributed to a $291.9 million net loss for St. Louis-based Mallinckrodt. The company also reported that earnings in its medical imaging business declined as a result of falling prices for contrast media.
For the year, Mallinckrodt reported sales of $2.37 billion, up sharply from $1.7 billion the year before, due to the acquisition of revenues from the Nellcor business. Earnings from continuing operations, not including charges related to the Nellcor purchase, were $132.9 million. Mallinckrodt posted a net profit of $190.1 million the prior year.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
